MELBOURNE, AUSTRALIA / ACCESSWIRE / November 18, 2024 / Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback